PriceTargets.com logo

Allergy Therapeutics - AGYTF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.08 As of 04/21/2025 01:00 AM ET
+0 (0.00%)
Get New Allergy Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGYTF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGYTF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Allergy Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.08.

This chart shows the closing price for AGYTF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Allergy Therapeutics. This rating has held steady since July 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/26/2022HC WainwrightReiterated RatingBuy
(Data available from 4/22/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
9/24/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
Mentions as of
10/24/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Allergy Therapeutics logo
Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Read More

Today's Range

Now: $0.08
Low: $0.08
High: $0.08

50 Day Range

MA: N/A

52 Week Range

Now: $0.08
Low: $0.17
High: $0.19

Volume

N/A

Average Volume

N/A

Market Capitalization

$56.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

525.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Allergy Therapeutics?

The following sell-side analysts have issued reports on Allergy Therapeutics in the last year:
View the latest analyst ratings for AGYTF.

What is the current price target for Allergy Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Allergy Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Allergy Therapeutics in the next year.
View the latest price targets for AGYTF.

What is the current consensus analyst rating for Allergy Therapeutics?

Allergy Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGYTF.

What other companies compete with Allergy Therapeutics?

Other companies that are similar to Allergy Therapeutics include VK International Public Joint-Stock, Capricorn Energy, Princeton Bancorp, SJM and The Taiwan Fund. Learn More about companies similar to Allergy Therapeutics.

How do I contact Allergy Therapeutics' investor relations team?

Allergy Therapeutics' physical mailing address is Dominion Way West Sussex, Worthing X0, BN14 8SA. The company's listed phone number is 44-19-0384-4700. The official website for Allergy Therapeutics is www.allergytherapeutics.com. Learn More about contacing Allergy Therapeutics investor relations.